Viridian Therapeutics price target lowered to $36 from $41 at Goldman Sachs

Goldman Sachs lowered the firm’s price target on Viridian Therapeutics (VRDN) to $36 from $41 and keeps a Buy rating on the shares. Viridian Therapeutics announced that elegrobart met the primary endpoint in the Phase 3 REVEAL-1 trial, with statistically significant proptosis responder rates for both Q4W and Q8W dosing versus placebo, along with meaningful diplopia resolution and a favorable safety profile, the analyst tells investors in a research note, adding that the 30% pullback is “unwarranted.” The company plans a 1Q27 BLA submission and intends to commercialize both regimens, though comparable efficacy and receptor saturation across doses could skew utilization toward the lower-priced Q8W option despite differentiation from competitors through IV and at-home SC offerings, the firm says.